Literature DB >> 27748596

Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.

Claire Le Manach1, Aloysius T Nchinda1, Tanya Paquet1, Diego Gonzàlez Cabrera1, Yassir Younis1, Ze Han1, Sridevi Bashyam2, Mohammed Zabiulla2, Dale Taylor3, Nina Lawrence3, Karen L White4, Susan A Charman4, David Waterson5, Michael J Witty5, Sergio Wittlin6,7, Mariëtte E Botha8, Sindisiswe H Nondaba8, Janette Reader8, Lyn-Marie Birkholtz8, María Belén Jiménez-Díaz9, María Santos Martínez9, Santiago Ferrer9, Iñigo Angulo-Barturen9, Stephan Meister10, Yevgeniya Antonova-Koch10, Elizabeth A Winzeler10, Leslie J Street1, Kelly Chibale1,11.   

Abstract

Introduction of water-solubilizing groups on the 5-phenyl ring of a 2-aminopyrazine series led to the identification of highly potent compounds against the blood life-cycle stage of the human malaria parasite Plasmodium falciparum. Several compounds displayed high in vivo efficacy in two different mouse models for malaria, P. berghei-infected mice and P. falciparum-infected NOD-scid IL-2Rγnull mice. One of the frontrunners, compound 3, was identified to also have good pharmacokinetics and additionally very potent activity against the liver and gametocyte parasite life-cycle stages.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27748596     DOI: 10.1021/acs.jmedchem.6b01265

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

Review 1.  Recent updates in the discovery and development of novel antimalarial drug candidates.

Authors:  John Okombo; Kelly Chibale
Journal:  Medchemcomm       Date:  2018-02-02       Impact factor: 3.597

2.  UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Authors:  Christel Brunschwig; Nina Lawrence; Dale Taylor; Efrem Abay; Mathew Njoroge; Gregory S Basarab; Claire Le Manach; Tanya Paquet; Diego Gonzàlez Cabrera; Aloysius T Nchinda; Carmen de Kock; Lubbe Wiesner; Paolo Denti; David Waterson; Benjamin Blasco; Didier Leroy; Michael J Witty; Cristina Donini; James Duffy; Sergio Wittlin; Karen L White; Susan A Charman; Maria Belén Jiménez-Díaz; Iñigo Angulo-Barturen; Esperanza Herreros; Francisco Javier Gamo; Rosemary Rochford; Dalu Mancama; Theresa L Coetzer; Mariëtte E van der Watt; Janette Reader; Lyn-Marie Birkholtz; Kennan C Marsh; Suresh M Solapure; John E Burke; Jacob A McPhail; Manu Vanaerschot; David A Fidock; Paul V Fish; Peter Siegl; Dennis A Smith; Grennady Wirjanata; Rintis Noviyanti; Ric N Price; Jutta Marfurt; Kigbafori D Silue; Leslie J Street; Kelly Chibale
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Enhanced Ex Vivo Plasmodium vivax Intraerythrocytic Enrichment and Maturation for Rapid and Sensitive Parasite Growth Assays.

Authors:  Gabriel W Rangel; Martha A Clark; Usheer Kanjee; Caeul Lim; Kathryn Shaw-Saliba; Maria José Menezes; Anjali Mascarenhas; Laura Chery; Edwin Gomes; Pradipsinh K Rathod; Marcelo U Ferreira; Manoj T Duraisingh
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  Investigating Sulfoxide-to-Sulfone Conversion as a Prodrug Strategy for a Phosphatidylinositol 4-Kinase Inhibitor in a Humanized Mouse Model of Malaria.

Authors:  Liezl Gibhard; Mathew Njoroge; Tanya Paquet; Christel Brunschwig; Dale Taylor; Nina Lawrence; Efrem Abay; Sergio Wittlin; Lubbe Wiesner; Leslie J Street; Kelly Chibale; Gregory S Basarab
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

5.  Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.

Authors:  Sandra Duffy; Melissa L Sykes; Amy J Jones; Todd B Shelper; Moana Simpson; Rebecca Lang; Sally-Ann Poulsen; Brad E Sleebs; Vicky M Avery
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery.

Authors:  John Okombo; Kelly Chibale
Journal:  Acc Chem Res       Date:  2017-06-21       Impact factor: 22.384

7.  Harmonizing solubility measurement to lower inter-laboratory variance - progress of consortium of biopharmaceutical tools (CoBiTo) in Japan.

Authors:  Asami Ono; Naoya Matsumura; Takahiro Kimoto; Yoshiyuki Akiyama; Satoko Funaki; Naomi Tamura; Shun Hayashi; Yukiko Kojima; Masahiro Fushimi; Hiroshi Sudaki; Risa Aihara; Yuka Haruna; Maiko Jiko; Masaru Iwasaki; Takuya Fujita; Kiyohiko Sugano
Journal:  ADMET DMPK       Date:  2019-08-05

8.  Plasmodial Kinase Inhibitors: License to Cure?

Authors:  Diego González Cabrera; André Horatscheck; Colin R Wilson; Greg Basarab; Charles J Eyermann; Kelly Chibale
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

Review 9.  Model-Informed Drug Development for Malaria Therapeutics.

Authors:  Kayla Ann Andrews; David Wesche; James McCarthy; Jörg J Möhrle; Joel Tarning; Luann Phillips; Steven Kern; Thaddeus Grasela
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-06       Impact factor: 13.820

Review 10.  An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors.

Authors:  Chantalle Moolman; Rencia van der Sluis; Richard M Beteck; Lesetja J Legoabe
Journal:  Molecules       Date:  2020-11-07       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.